Medivir AB
Company Profile
Business description
Medivir AB develops therapies targeting diseases with high unmet medical need. The group's drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Its two programs are fostrox, designed to target liver cancer cells while minimizing side effects selectively, and MIV-711, aimed at treating Osteogenesis Imperfecta (Brittle bone disease) and Legg-Calve-Perthes disease (Perthes disease). It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. It also has four out-licensed projects, Xerclear, MIV-701, MBLI/MET-X, and remetinostat. Geographic revenue is generated from Europe and other regions.
Contact
Lunastigen 5
PO Box 1086, 2nd floor
Huddinge141 22
SWET: +46 854683100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during June?
stocks
Australia’s largest gold miner downgraded on a falling gold price
stocks
Cheap ASX share pays a heavy price for NRL rights
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,001.30 | 3.70 | 0.04% |
| CAC 40 | 8,366.85 | 2.20 | 0.03% |
| DAX 40 | 25,147.03 | 32.78 | 0.13% |
| Dow JONES (US) | 52,508.27 | 9.63 | 0.02% |
| FTSE 100 | 10,529.39 | 31.10 | 0.30% |
| HKSE | 24,340.73 | 127.01 | 0.52% |
| NASDAQ | 26,107.01 | 233.83 | 0.90% |
| Nikkei 225 | 67,743.50 | 500.77 | 0.74% |
| NZX 50 Index | 13,651.22 | 71.98 | -0.52% |
| S&P 500 | 7,543.59 | 28.25 | 0.38% |
| S&P/ASX 200 | 8,808.50 | 4.80 | 0.05% |
| SSE Composite Index | 3,967.13 | 53.33 | 1.36% |